Week in Review: China to Set Time Limit on Drug Approval Process

China's State Council told the CFDA to establish a definite time limit for drug approvals along with other broad initiatives for improving  drug approvals; the CFDA will ease regulations governing simultaneous China-global clinical trials of innovative drugs and allow more data from global trials; Burning Rock Biotech of Guangzhou completed a $23 million Series A+ round to advance its oncology diagnostics products; Singapore's Asian American Medical Group paid $14 million for a 60% interest in a Zhuhai outpatient medical center, Anpac Bio-Medical Science of Shanghai announced a Series A investment of several million dollars for its cancer screening technology; China's Hutchison MediPharma will continue to develop HMP-507, a small molecule anti-inflammation drug, after Janssen ended their collaboration; BeiGene of Beijing will build a cGMP manufacturing facility in Suzhou's BioBAY for its oncology drug portfolio. More details.... Share this with colleagues: // //